Free Trial

Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down - Should You Sell?

Merck KGaA logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Merck KGaA shares gapped down about 6.5%, opening at $133.92 versus a prior close of $143.29 and last trading at $138.96, with very light volume (141 shares).
  • The stock has a market cap of $17.31 billion, a P/E of 20.45 and modest leverage (debt/equity 0.27), while liquidity metrics show a quick ratio below 1 (0.84) and a current ratio of 1.31.
  • Merck KGaA is a long-established, family-controlled German chemical and pharmaceutical group (the Merck Group) with global operations across Europe, the Americas and Asia-Pacific.
  • MarketBeat previews top five stocks to own in May.

Merck KGaA (OTCMKTS:MKGAF - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $143.29, but opened at $133.9190. Merck KGaA shares last traded at $138.9610, with a volume of 141 shares changing hands.

Merck KGaA Stock Down 6.5%

The stock has a market cap of $17.31 billion, a price-to-earnings ratio of 20.45 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The stock has a fifty day moving average of $136.79 and a two-hundred day moving average of $139.76.

Merck KGaA Company Profile

(Get Free Report)

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck KGaA Right Now?

Before you consider Merck KGaA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.

While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines